1. Metformin is not efficient enough in order to regulate menstrual cycles. 2.Metformin is not efficient enough in order to treat hyperandrogenism. 3. Metformin should not be used as a first-line treatment in order to treat infertility. Clomiphene citrate (CC) is the reference treatment. 4. Metformin in addition to CC is not recommended as a second line treatment, after the failure of CC alone....

A new formulation of metformin: metformin extendedrelease (ER) is now available, with different formulations in each country and it appears relevant to discuss the management of this drug in clinical practice. Metformin, an oral biguanide hypoglycemic agent, is an efficacious tool in the treatment of type 2 diabetes mellitus. Metformin’s efficacy, security profile, benefic cardiovascular and me...

A number of factors have been identified that increase the risk of hepatocellular carcinoma (HCC). Recently it has become appreciated that type II diabetes increases the risk of developing HCC. This represents a patient population that can be identified and targeted for cancer prevention. The biguanide metformin is a first-line therapy for the treatment of type II diabetes in which it exerts it...

Metformin is an anti-hyperglycemic agent used to treat diabetes, and recent evidence suggests it has antitumor efficacy. Because growth hormone-secreting pituitary adenoma (GH-PA) patients have a high incidence of diabetes frequently treated with metformin, we assessed the antitumor effect of metformin on GH-PA. We found that metformin effectively inhibited proliferation and induced apoptosis i...

diabetes is a metabolic disorder which affects whole body systems including reproductive system. diabetes is also a contributing factor to infertility. metformin is one of the most common drugs to control hyperglycemia. in this study, 36 adult sprague-dawley female rats (170-210 g) were divided into 3 groups (control, diabetic and diabetic-treated by metformin). in second and third groups, diab...

Participants from DPP/DPPOS were assigned to placebo (n=1082) or metformin (n=1073) for 3.2 years, followed by metformin in the metformin group for 9 years. Metformin use was associated with increased risk of vitamin B12 deficiency.

OBJECTIVE To evaluate the metabolic and endocrine effects of treatment with cyclic medroxyprogesterone acetate (MPA) plus metformin compared with metformin alone in women with PCOS. METHODS In this prospective randomized study of women with PCOS, 20 women received 850 mg of metformin twice a day, and 20 women received 850 mg of metformin plus 5 mg of MPA twice a day. Body mass index, hormonal...

Metformin is a commonly used oral anti-hyperglycemic agent of the biguanide family. Recent studies suggest that metformin may reduce cancer risk and improve prognosis. However, the antitumor mechanism of metformin in several types of cancers, including hepatocellular carcinoma (HCC), has not been elucidated. The goal of the present study was to evaluate the effects of metformin on HCC cell prol...

Metformin is commonly used in the treatment of diabetes, however recently there is increasing interest in “repurposing” the drug for cancer prevention or treatment. Metformin is believed to act by inhibiting mitochondrial complex I, leading to activation of AMPK. Interestingly, metformin treatment is not associated with the serious health consequences that are seen with classic inhibitors of co...